Buscar
GSK plc
GSKAñadir a la lista de seguimiento
50.470USD
+0.060+0.12%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
102.32BCap. mercado
13.01P/E TTM
Más Datos de GSK plc Compañía
GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
Información de GSK plc
Símbolo de cotizaciónGSK
Nombre de la empresaGSK plc
Fecha de salida a bolsaMay 22, 1972
Director ejecutivoWaterhouse (Deborah)
Número de empleados68629
Tipo de seguridadDepository Receipt
Fin del año fiscalMay 22
Dirección980 Great West Road
CiudadBRENTFORD
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited Kingdom
Código postalTW8 9GS
Teléfono442080475000
Sitio Webhttps://www.gsk.com/
Símbolo de cotizaciónGSK
Fecha de salida a bolsaMay 22, 1972
Director ejecutivoWaterhouse (Deborah)
Ejecutivos de GSK plc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Hal V. Barron, M.D.
Dr. Hal V. Barron, M.D.
Non-Executive Director
Non-Executive Director
602.15K
+0.00%
Ms. Shobie Ramakrishnan
Ms. Shobie Ramakrishnan
Chief Digital and Technology Officer
Chief Digital and Technology Officer
514.11K
+0.12%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
41.23K
+0.76%
Ms. Elizabeth McKee (Liz) Anderson
Ms. Elizabeth McKee (Liz) Anderson
Independent Non-Executive Director
Independent Non-Executive Director
3.45K
+0.75%
Dr. Jeannie Lee
Dr. Jeannie Lee
Independent Non-Executive Director and Scientific & Medical Expert
Independent Non-Executive Director and Scientific & Medical Expert
2.00K
+0.70%
Mr. David S. Redfern
Mr. David S. Redfern
President - Corporate Development
President - Corporate Development
--
--
Ms. Victoria Anne Whyte
Ms. Victoria Anne Whyte
Company Secretary
Company Secretary
--
--
Mr. Phil C. Thomson
Mr. Phil C. Thomson
President - Global Affairs
President - Global Affairs
--
--
Dame Emma N. Walmsley
Dame Emma N. Walmsley
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Luke Miels
Mr. Luke Miels
Chief Executive Officer - Designate, Director
Chief Executive Officer - Designate, Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Hal V. Barron, M.D.
Dr. Hal V. Barron, M.D.
Non-Executive Director
Non-Executive Director
602.15K
+0.00%
Ms. Shobie Ramakrishnan
Ms. Shobie Ramakrishnan
Chief Digital and Technology Officer
Chief Digital and Technology Officer
514.11K
+0.12%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
41.23K
+0.76%
Ms. Elizabeth McKee (Liz) Anderson
Ms. Elizabeth McKee (Liz) Anderson
Independent Non-Executive Director
Independent Non-Executive Director
3.45K
+0.75%
Dr. Jeannie Lee
Dr. Jeannie Lee
Independent Non-Executive Director and Scientific & Medical Expert
Independent Non-Executive Director and Scientific & Medical Expert
2.00K
+0.70%
Mr. David S. Redfern
Mr. David S. Redfern
President - Corporate Development
President - Corporate Development
--
--
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de abr
Divisa: USDActualizado: lun., 6 de abr
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
HIV
10.12B
23.53%
Respiratory
9.31B
21.64%
Immuno-inflammation
5.02B
11.66%
Shingles
4.69B
10.89%
Established Vaccines
4.11B
9.55%
Otro
9.78B
22.73%
Por regiónUSD
Nombre
Ganancia
Proporción
US
22.20B
51.61%
Rest of world
10.90B
25.33%
Europe
9.92B
23.06%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
HIV
10.12B
23.53%
Respiratory
9.31B
21.64%
Immuno-inflammation
5.02B
11.66%
Shingles
4.69B
10.89%
Established Vaccines
4.11B
9.55%
Otro
9.78B
22.73%
Estadísticas de accionistas
Actualizado: jue., 7 de may
Actualizado: jue., 7 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Dodge & Cox
3.38%
Fidelity Management & Research Company LLC
2.81%
Fisher Investments
1.70%
PRIMECAP Management Company
1.24%
JTC Employer Solutions Trusteee Ltd
0.71%
Otro
90.16%
Accionistas
Accionistas
Proporción
Dodge & Cox
3.38%
Fidelity Management & Research Company LLC
2.81%
Fisher Investments
1.70%
PRIMECAP Management Company
1.24%
JTC Employer Solutions Trusteee Ltd
0.71%
Otro
90.16%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
9.05%
Investment Advisor/Hedge Fund
8.17%
Research Firm
1.01%
Hedge Fund
0.92%
Pension Fund
0.13%
Bank and Trust
0.10%
Individual Investor
0.06%
Family Office
0.03%
Family Office
0.02%
Otro
80.52%
Participación institucional
Actualizado: mié., 1 de abr
Actualizado: mié., 1 de abr
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q1
1585
393.46M
19.40%
-23.49M
2025Q4
1508
391.56M
19.21%
-21.81M
2025Q3
1474
388.63M
19.14%
-11.70M
2025Q2
1478
378.08M
18.54%
+5.70M
2025Q1
1494
378.46M
18.50%
+5.08M
2024Q4
1481
355.06M
17.14%
+27.38M
2024Q3
1472
319.97M
15.44%
-30.07M
2024Q2
1585
322.06M
15.54%
-29.11M
2024Q1
1617
318.91M
15.39%
-23.52M
2023Q4
1614
299.81M
14.57%
-35.71M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Dodge & Cox
68.52M
3.37%
-9.89M
-12.61%
Dec 31, 2025
Fidelity Management & Research Company LLC
56.97M
2.81%
+1.14M
+2.04%
Dec 31, 2025
Fisher Investments
33.20M
1.64%
+968.37K
+3.00%
Dec 31, 2025
PRIMECAP Management Company
25.13M
1.24%
-636.79K
-2.47%
Dec 31, 2025
JTC Employer Solutions Trusteee Ltd
14.43M
0.71%
-169.18K
-1.16%
Dec 31, 2025
Wellington Management Company, LLP
12.56M
0.62%
+9.14M
+267.14%
Dec 31, 2025
Acadian Asset Management LLC
8.96M
0.44%
+6.18M
+221.47%
Dec 31, 2025
Fidelity Institutional Asset Management
8.15M
0.4%
+179.23K
+2.25%
Dec 31, 2025
Holocene Advisors, LP
8.12M
0.4%
+1.02M
+14.31%
Dec 31, 2025
T. Rowe Price International Ltd
7.89M
0.39%
-56.47K
-0.71%
Dec 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
VanEck Pharmaceutical ETF
10.83%
The Opal International Dividend Income ETF
4.41%
Sound Equity Dividend Income ETF
3.97%
Keating Active ETF
3.88%
USCF Dividend Income Fund
3.83%
Brandes International ETF
2.87%
Altrius Global Dividend ETF
2.58%
Fidelity Blue Chip Value ETF
1.6%
Lattice Hartford Mltfctr Dev Mkts (ex-US) Str ETF
1.17%
Avantis International Large Cap Value ETF
1.02%
Ver más
VanEck Pharmaceutical ETF
Proporción10.83%
The Opal International Dividend Income ETF
Proporción4.41%
Sound Equity Dividend Income ETF
Proporción3.97%
Keating Active ETF
Proporción3.88%
USCF Dividend Income Fund
Proporción3.83%
Brandes International ETF
Proporción2.87%
Altrius Global Dividend ETF
Proporción2.58%
Fidelity Blue Chip Value ETF
Proporción1.6%
Lattice Hartford Mltfctr Dev Mkts (ex-US) Str ETF
Proporción1.17%
Avantis International Large Cap Value ETF
Proporción1.02%
Dividendos
Un total de
15.69B
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
May 04, 2026
GSK.NB Approximate interim Cash Dividend of gross USD 0.461074 paid on Jul 09, 2026 going ex on May 15, 2026
May 15, 2026
Jul 09, 2026
May 15, 2026
Apr 29, 2026
GSK.NB Interim Cash Dividend of gross paid on Jul 09, 2026 going ex on May 15, 2026
May 15, 2026
Jul 09, 2026
May 15, 2026
Feb 05, 2025
GSK.NB Interim Cash Dividend of gross USD 0.434774 paid on Jul 10, 2025 going ex on May 16, 2025
May 16, 2025
Jul 10, 2025
May 16, 2025
Feb 05, 2025
GSK.NB Interim Cash Dividend of gross USD 0.42996 paid on Oct 09, 2025 going ex on Aug 15, 2025
Aug 15, 2025
Oct 09, 2025
Aug 15, 2025
Feb 05, 2025
GSK.NB Approximate final Cash Dividend of gross USD 0.417088 paid on Jan 08, 2026 going ex on Nov 14, 2025
Nov 14, 2025
Jan 08, 2026
Nov 14, 2025
Feb 05, 2025
GSK.NB Interim Cash Dividend of gross USD 0.407568 paid on Apr 10, 2025 going ex on Feb 21, 2025
Feb 21, 2025
Apr 10, 2025
Feb 21, 2025
Feb 05, 2025
GSK.NB Approximate interim Cash Dividend of gross paid on Apr 09, 2026 going ex on Feb 20, 2026
Feb 20, 2026
Apr 09, 2026
Feb 20, 2026
Oct 30, 2024
GSK.NB Final Cash Dividend of gross USD 0.376892 paid on Jan 09, 2025 going ex on Nov 15, 2024
Nov 15, 2024
Jan 09, 2025
Nov 15, 2024
Jul 31, 2024
GSK.NB Interim Cash Dividend of gross USD 0.392813 paid on Oct 10, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Oct 10, 2024
Aug 16, 2024
May 01, 2024
GSK.NB Interim Cash Dividend of gross USD 0.384301 paid on Jul 11, 2024 going ex on May 16, 2024
May 17, 2024
Jul 11, 2024
May 16, 2024
Ver más
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Jun 24, 2022
Merger
5→4
Jun 24, 2022
Merger
5→4
Jun 24, 2022
Merger
5→4
Jun 24, 2022
Merger
5→4
Fecha
Fecha ex-dividendo
Tipo
Relación
Jun 24, 2022
Merger
5→4
Jun 24, 2022
Merger
5→4
Jun 24, 2022
Merger
5→4
Jun 24, 2022
Merger
5→4
